United Kingdom Male Hypogonadism Market Insight
The United Kingdom Male Hypogonadism Market is growing at an 6.62% CAGR, driven by rising testosterone deficiency, increasing men’s health awareness, and NHS access, the market grows with adoption of TRT gels, injections, and patches, while AbbVie innovations improve effectiveness, safety, and long-term outcomes
United Kingdom Male Hypogonadism Market Insights Forecasts to 2035
- The United Kingdom Male Hypogonadism Market Size Was Estimated at USD 3.89 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.62% from 2025 to 2035
- The United Kingdom Male Hypogonadism Market Size is Expected to Reach USD 7.38 Billion by 2035
Notable Insights for United Kingdom Male Hypogonadism Market
- By product type, testosterone replacement therapies (TRT) dominated, accounting for approximately 60–65% share in 2024, driven by widespread use of gels and injections for testosterone deficiency management.
- By therapy type, topical gels dominated, holding approximately 40–45% share, due to ease of administration and steady hormone delivery.
- Approximately 2–5% of men in the UK are affected by clinically significant hypogonadism, with prevalence increasing to 20–30% with age, particularly in men above 50 years.
- Around 60–70% of diagnosed patients receive TRT, mainly gels and injections. Nearly 40% of men remain undiagnosed, while long-acting injectables account for 25–30% of usage due to better compliance and convenience.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Male Hypogonadism Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Male Hypogonadism Market
- AbbVie
- Endo International
- Pfizer Inc.
- Bayer AG
- Mylan N.V.
- Teva Pharmaceutical Industries
- Ferring Pharmaceuticals
- Sanofi
- GlaxoSmithKline
- AstraZeneca
- Others
Recent Developments:
- In November 2024: Numan expanded its TRT services by appointing specialist clinicians, strengthening digital hormone care offerings and supporting rising demand for male hypogonadism treatment in the UK.
- In March 2023: Endo International reported growth in testosterone therapy sales, driven by increasing hypogonadism diagnosis and rising demand for long-acting injectable treatments globally.
Market Segmentation:
United Kingdom Male Hypogonadism Market, By Product Type
- Testosterone Replacement Therapy (TRT)
- Gonadotropins
- Others
United Kingdom Male Hypogonadism Market, By Therapy Type
- Topical Gels
- Injections
- Transdermal Patches
- Oral Therapy
United Kingdom Male Hypogonadism Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK OMale Hypogonadism Market is expected to grow steadily due to increasing awareness of menopause management and rising demand for personalized treatment options. Experts highlight that transdermal and low-dose oestrogen therapies will dominate the market. With strong NHS support and evolving clinical guidelines, demand for safe, effective, and long-term hormone replacement solutions is expected to increase, ensuring sustained market growth.